People's General Hospital is a public teaching hospital in Athens, Greece. The hospital belongs to the Greek National Healthcare System under the 1st Healthcare Region of Attica and comprises numerous clinics, labs, inpatient wards and outpatient departments.

During the past decade, LAIKO General Hospital of Athens conducted 105 clinical trials. In the 10-year time frame, 105 clinical trials started and 41 clinical trials were completed, i.e. on average, 39% percent of trials that started reached the finish line to date. In the past 5 years, 58 clinical trials started and 27 clinical trials were completed. i.e. 46.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "LAIKO General Hospital of Athens" #1 sponsor was "Hoffmann-La Roche" with 18 trials, followed by "Amgen" with 14 trials sponsored, "Celgene" with 11 trials sponsored, "Pfizer" with 7 trials sponsored and "Bayer" with 7 trials sponsored. Other sponsors include 79 different institutions and companies that sponsored additional 61 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "LAIKO General Hospital of Athens" #1 collaborator was "Janssen Research & Development, LLC" with 3 trials as a collaborator, "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)" with 2 trials as a collaborator, "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 2 trials as a collaborator, "Assistance Publique - Hôpitaux de Paris" with 2 trials as a collaborator and "Linkoeping University" with 2 trials as a collaborator. Other collaborators include 67 different institutions and companies that were collaborators in the rest 66 trials.

According to Clinical.Site data, the most researched conditions in "LAIKO General Hospital of Athens" are "Melanoma" (7 trials), "Rheumatoid Arthritis" (7 trials), "Multiple Myeloma" (5 trials), "Crohn Disease" (3 trials) and "Follicular Lymphoma" (3 trials). Many other conditions were trialed in "LAIKO General Hospital of Athens" in a lesser frequency.

Most popular intervention types in "LAIKO General Hospital of Athens" are "Drug" (108 trials), "Other" (15 trials), "Biological" (6 trials), "Behavioral" (2 trials) and "Diagnostic Test" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (39 trials), "Atezolizumab" (5 trials), "Pembrolizumab" (4 trials), "Rituximab" (4 trials) and "Tocilizumab" (4 trials). Other intervention names were less common.

The vast majority of trials in "LAIKO General Hospital of Athens" are 135 trials for "All" genders, 4 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "LAIKO General Hospital of Athens". undefined are not yet recruiting, 33 are recruiting, 25 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 70 completed trials in LAIKO General Hospital of Athens, undefined suspended trials, and 10 terminated clinical trials to date.

Out of the total trials that were conducted in LAIKO General Hospital of Athens, 1 "Phase 1" clinical trials were conducted, 33 "Phase 2" clinical trials and 69 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 6 trials, and there were also 6 trials that are defined as “Not Applicable".